Lumos Pharma Inc Quick Ratio (LUMO) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lumos Pharma Inc   (NASDAQ: LUMO)

Lumos Pharma Inc 's Quick Ratio

LUMO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 2.12 below Lumos Pharma Inc average.

Within Major Pharmaceutical Preparations industry 308 other companies have achieved higher Quick Ratio than Lumos Pharma Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 1122 to 1528.

Explain Quick Ratio?
How much Cash & cash equivalents LUMO´s has?
What are LUMO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LUMO Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change 6.43 % -27.25 % -17.86 % 0.6 % 9.25 %
Y / Y Cash & cash equivalent Change -68.34 % -66.96 % -60.02 % -46.44 % -42.04 %
Quick Ratio MRQ 2.12 3.63 5.62 5.35 7.13
LUMO's Total Ranking # 1528 # 1122 # 832 # 968 # 704
Seq. Current Liabilities Change 37.66 % 12.38 % -38.93 % 12.65 % -5.91 %
Seq. Cash & cash equivalent Change -19.52 % -27.52 % -35.75 % -15.5 % -16.04 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 309
Healthcare Sector # 543
Overall Market # 1475


Quick Ratio Statistics
High Average Low
22.89 6.53 0.06
(Mar 31 2021)   (Jun 30 2013)




Financial Statements
Lumos Pharma Inc 's Current Liabilities $ 6 Millions Visit LUMO's Balance sheet
Lumos Pharma Inc 's Cash & cash equivalent $ 14 Millions Visit LUMO's Balance sheet
Source of LUMO's Sales Visit LUMO's Sales by Geography


Cumulative Lumos Pharma Inc 's Quick Ratio

LUMO's Quick Ratio for the trailling 12 Months

LUMO Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -9.16 % -8.84 % 5.38 % 8.34 % 16.41 %
Y / Y Cash & cash equivalent TTM Growth -59.08 % -52.47 % -45.14 % -38.95 % -34.61 %
Quick Ratio TTM 4.09 5.53 6.58 7.78 9.09
Total Ranking TTM # 3271 # 3075 # 3142 # 2449 # 315
Seq. Current Liabilities TTM Growth 1.79 % -7.47 % -3.71 % 0.17 % 2.15 %
Seq. Cash & cash equivalent TTM Growth -24.57 % -22.29 % -18.55 % -14.29 % -12.4 %

Quick ratio ranking by company, industry and sector >> Back to LUMO Financial Strength Comparisons >> Go to Compare LUMO Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2024 to $6.38 millions, cumulative Quick Ratio decreased to 4.09 below the Lumos Pharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 440 other companies have achieved higher Quick Ratio than Lumos Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3075 to 3271.

Explain Quick Ratio?
How much Cash & cash equivalents LUMO´s has?
What are LUMO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 441
Healthcare Sector # 912
Within the Market # 3271


trailing twelve months Quick Ratio Statistics
High Average Low
18.19 6.17 0.04
(Dec 31 2021)   (March 31, 2014)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Allakos Inc   5.80 $ 92.715  Millions$ 15.981  Millions
Repare Therapeutics Inc   5.77 $ 179.432  Millions$ 31.084  Millions
Madrigal Pharmaceuticals Inc   5.64 $ 998.627  Millions$ 176.969  Millions
Vyne Therapeutics Inc   5.60 $ 70.232  Millions$ 12.538  Millions
Tvardi Therapeutics Inc   5.60 $ 37.061  Millions$ 6.622  Millions
Inmed Pharmaceuticals Inc  5.56 $ 5.626  Millions$ 1.012  Millions
Calcimedica Inc   5.45 $ 14.603  Millions$ 2.679  Millions
Bullfrog Ai Holdings Inc   5.44 $ 4.239  Millions$ 0.779  Millions
Renovorx Inc   5.40 $ 9.563  Millions$ 1.772  Millions
Monopar Therapeutics Inc   5.36 $ 6.020  Millions$ 1.123  Millions
Azitra Inc   5.31 $ 7.260  Millions$ 1.368  Millions
Phathom Pharmaceuticals Inc   5.13 $ 334.678  Millions$ 65.288  Millions
Arcus Biosciences Inc   5.07 $ 1,089.000  Millions$ 215.000  Millions
Spruce Biosciences Inc   5.06 $ 60.055  Millions$ 11.858  Millions
Io Biotech Inc   4.99 $ 80.185  Millions$ 16.055  Millions
Igm Biosciences Inc   4.98 $ 218.787  Millions$ 43.964  Millions
Foghorn Therapeutics Inc   4.71 $ 267.397  Millions$ 56.824  Millions
Chemomab Therapeutics Ltd   4.60 $ 14.266  Millions$ 3.103  Millions
Alx Oncology Holdings Inc  4.59 $ 148.574  Millions$ 32.340  Millions
Sol gel Technologies Ltd   4.53 $ 23.926  Millions$ 5.285  Millions
Clearside Biomedical Inc   4.52 $ 23.591  Millions$ 5.220  Millions
Amylyx Pharmaceuticals Inc   4.35 $ 234.395  Millions$ 53.915  Millions
Enanta Pharmaceuticals Inc  4.31 $ 248.186  Millions$ 57.535  Millions
Cryoport inc   4.25 $ 260.860  Millions$ 61.439  Millions
Catalyst Pharmaceuticals Inc   4.20 $ 442.331  Millions$ 105.395  Millions
Addex Therapeutics Ltd  4.17 $ 3.685  Millions$ 0.885  Millions
Cyclerion Therapeutics Inc   4.10 $ 2.872  Millions$ 0.700  Millions
Arvinas Inc   4.07 $ 1,121.600  Millions$ 275.900  Millions
Atrium Therapeutics Inc   4.05 $ 370.187  Millions$ 91.333  Millions
Talphera Inc   4.02 $ 11.117  Millions$ 2.762  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.